News

Astellas Pharma Europe registered and launched luteinizing hormone-releasing hormone (LHRH) agonist Eligard in majority of European countries. Under the terms of the new agreement, the commercialization of Eligard

Oxford Outcomes provides specialist services in the areas of patient reported outcomes (PRO), health economics, epidemiology and translation and linguistic validation. Elizabeth Thiele, former ICON executive vice president

Through the new business unit, Callidus extends its footprint to provide sales lifecycle management solutions in the pharmaceutical and life sciences industry. The solutions are expected to optimize

Peramivir is an intravenously administered investigational anti-viral agent, which delivers high plasma concentrations to the sites of infection. The open-label, randomised, safety and virology Phase III study evaluated

Dronedarone is indicated for the treatment of abnormal heart rhythm in patients who have had an abnormal heart rhythm during the past six months. According to the FDA,

Nabumetone is in a group of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs) and it works by reducing hormones that cause inflammation and pain in the body. Nabumetone is

Tracer trial is evaluating patients with acute coronary syndrome; however, TRA-2P (also known as TIMI 50) is assessing patients with prior heart attack, stroke and peripheral artery disease.

As per the terms of the agreement, Orexo is expected to take up the responsibly for supplying Abstral product to Invida. However, Invida will be responsible for all

Exparel is a novel, sustained-release analgesic formulation of bupivacaine HCl. The study demonstrated that the median time to first use of opioid rescue medication was 7.2 hours for